FDA fast tracks approval for Merck’s Genetically modified Ebola Vaccine

Merck has received the FDA’s fast-tracked approval of a live, genetically modified Ebola vaccine which, according to its vaccine insert, can cause a novel new form of Ebola-type infection, resulting in immunosuppression and possible shedding of live virus to others.

“ Transmission of vaccine virus is a theoretical possibility. Vaccine virus RNA has been detected in blood, saliva, or urine for up to 14 days after vaccination. The duration of shedding is not known; however, samples taken 28 days after vaccination tested negative. Vaccine virus RNA has been detected in fluid from skin vesicles that appeared after vaccination.”

READ More...

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.